Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Shirasugi Y et al. - No binding antibodies to romiplostim or thrombopoietin were detected. Romiplostim is safe and well tolerated in Japanese patients with chronic ITP and is effective in producing platelet count increases, consistent with the results from studies in non-Japanese patients. On the basis of these findings, a starting dose of 3ug/kg was recommended for phase III evaluation of romiplostim in Japanese patients with chronic ITP.


Today in Coagulation/Bleeding Dz...keeping you current

Management of the antiphospholipid syndrome: new approaches
International Journal of Clinical Rheumatology, 10/19/09

Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
Annals of Hematology, 10/23/09

Sickle cell disease and stroke
Blood, 10/13/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address